Fortnightly Review: The therapeutic use of bisphosphonates
- 17 September 1994
- Vol. 309 (6956), 711-715
- https://doi.org/10.1136/bmj.309.6956.711
Abstract
Bisphosphonates are characterised by two carbon-phosphorus bonds, the carbon atom replacing the oxygen in the P-O-P (phosphorus-oxygen- phosphorus) bond of pyrophosphate (fig 1) and the P-C-P (phosphorus carbon-phosphorus) bond conferring resistance to chemical and enzymatic hydrolysis. Different substitutions on the carbon atom have created several different bisphosphonates, each with its own individual pharmacological properties. The first bisphosphonate to be used therapeutically was etidronate, and subsequently many others have been developed. In order of increasing potency of antiresorptive activity the main bisphosphonates are etidronate, tiludronate, clodronate, pamidronate, alendronate, and risendronate.Keywords
This publication has 19 references indexed in Scilit:
- INTERMITTENT CYCLICAL ETIDRONATE IN THE PREVENTION OF CORTICOSTEROID-INDUCED BONE LOSSRheumatology, 1994
- Journal of Bone and Mineral ResearchJournal of Bone and Mineral Research, 1993
- Drugs Used in the Treatment of Metabolic Bone DiseaseDrugs, 1993
- Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosisJournal of Bone and Mineral Research, 1993
- Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.Thorax, 1992
- The use of bisphosphonates in the treatment of osteoporosisBone, 1992
- BisphosphonatesDrugs, 1991
- Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 1990
- TWO-YEAR FOLLOW-UP OF BIPHOSPHONATE (APD) TREATMENT IN STEROID OSTEOPOROSISThe Lancet, 1988
- PREVENTION OF STEROID-INDUCED OSTEOPOROSIS WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (APD)The Lancet, 1988